Johnson & Johnson privately contacted rivals for the Covid-19 vaccine to ask them to join forces to study the risks of blood clots and speak with one voice about safety, but Pfizer Inc. and Modern Inc. they declined.
As for last week, there were concerns about rare cases of blood clots, J&J asked AstraZeneca PLC, as well as Pfizer and Moderna, to join forces in examining the reports, people familiar with the case said. theme. J&J, through emails and phone calls, also tried to build an informal alliance to communicate the benefits and risks of the shootings and address any concerns citizens may cause about blood clots, according to some of the people.
Six women who received the J&J vaccine developed clots and one died, from more than seven million doses administered across the United States, according to federal health officials. People who received the shots from Pfizer and Moderna did not report the specific adverse event, officials said.
Pfizer and Moderna executives turned down the offer, saying their vaccines seemed safe, according to people. The couple also objected because they did not see the need to duplicate the efforts of regulators and companies that were already looking for cases of blood clots and investigating the cause, according to people. Some of the people said that the security of Pfizer and Moderna shots could be tarnished by the association.
Only AstraZeneca, who had been killed for similar blood clotting problems for weeks, agreed, people said.